The 35th Congress of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019)
Atara Biotherapeutics will present a presentation of initial ATA188 Phase 1 safety and efficacy results for patients with progressive multiple sclerosis (MS) at the 35th Congress of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019), which will take place in Stockholm Sweden, September 11 to 13, 2019.
Details of the presentation are as follows:
P1657: Preliminary safety and efficacy of ATA188, a pre-manufactured, unrelated donor (off-the-shelf, allogeneic) Epstein-Barr virus-targeted Tcell immunotherapy for patients with progressive forms of multiple sclerosis
Poster Presentation Date and Time: Friday, September 13, 2019, 12:15pm - 2:15pm CEST